Dyne Therapeutics (DYN) Net Equity Issued and Repurchased (2020 - 2025)

Dyne Therapeutics (DYN) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $377.7 million in Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $377.7 million in Q4 2025; TTM through Mar 2026 was $377.7 million, a 129.04% increase from a year earlier, with the FY2025 full-year figure at $140.7 million, up 43.71% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $377.7 million, up from $140.7 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for DYN reached as high as $377.7 million in Q4 2025 and fell as low as -$1000.0 in Q4 2023.
• Historically, Net Equity Issued and Repurchased has averaged $95.5 million across 3 years, with a median of $28.2 million in 2023.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 160.81% in 2024 and fell as far as 0.45% in 2024.
• Year by year, Net Equity Issued and Repurchased stood at -$1000.0 in 2023, then soared by 2425100.0% to $24.2 million in 2024, then surged by 1457.53% to $377.7 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $377.7 million in Q4 2025, $140.7 million in Q1 2025, and $24.2 million in Q2 2024.